Ikarovec was formed as a spin-out from the biotechnology company Quethera, which was acquired by Astellas Pharmaceuticals in 2018. It is a pre-clinical phase gene therapy company. The company has an early-stage pipeline of novel, multi-cistronic gene therapy products targeting diabetic macular edema (DME), age-related macular degeneration (AMD, both wet and dry forms), and ocular hypertension.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.